Unfortunately, some of us here have been suspecting this, due to personal experience:
"Twenty-three patients received Xofigo at UF Health, and one was lost to follow-up. Sixteen patients (73%) completed the full course (six doses) of Xofigo, while six did not. Ten patients (45%) developed pancytopenia, with two recovering counts within eight months while the other eight had persistent cytopenias (six of which were transfusion-dependent). Older age and higher ECOG score correlated with increased risk of pancytopenia. In addition, a higher percentage of patients who received prior radiation therapy were more likely to develop pancytopenia (90% vs 75%). Conclusions We found a higher rate of Xofigo-induced pancytopenia in our patient population than the 2% reported in the literature, albeit with a limited sample size,"
Cureus. 2020 Jan 28;12(1):e6806. doi: 10.7759/cureus.6806.
A Single-center Retrospective Analysis of the Effect of Radium-223 (Xofigo) on Pancytopenia in Patients with Metastatic Castration-resistant Prostate Cancer.
ncbi.nlm.nih.gov/pubmed/321...
Another study, from Dec 2017:
"The analysis of these parameters suggests that, in patients with a high skeletal tumor burden, the incidence of bone marrow failure in the course of radionuclide therapy could be higher than what reported previously. Further prospective studies are needed in order to confirm these data."
Tumor Burden and Intraosseous Metabolic Activity as Predictors of Bone Marrow Failure during Radioisotope Therapy in Metastasized Prostate Cancer Patients